Huachenyang (Shenzhen) Tech Co., Ltd. was founded in 2008, and in the 14 years since its establishment, the company has owned 79 patents. It has been focusing on biological consumables and reagents, taking a leading position in the field.
Huachenayng has established good relationships with more than 30 universities, 50 national research institutions, and 200 tertiary hospitals in China. More than 10 experiments/projects published in Nature, Cell, and EClinicalMedicine have chosen Huachenyang’s swabs.
Some of the projects that used Huachenyang’s swabs
1.
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
More and more scientific research, medical and governmental institutions choose Huachenyang’s products, which is not only the recognition and trust of our products but also gives us an additional responsibility. Huachenyang will continue to increase its independent research and development investment, actively introduce high-end biotechnology talents and technology, continue to deepen its work in the field of biological consumables and reagents and continue to provide the market with high-quality and stable products.
“HCY, Health care for you” is our forever mission. We dedicate to offering safe & reliable products and medical services with our global creditable partners. HCY has already supplied to WHO, MAYO clinic, MGI, DDC, Yale University, Qorvo, Quanterix, Thomas Scientific, SD biosensor, Cardinal Health, Cleveland Clinic, Mars Petcare & LumiraDx, etc. in the past years.
At present, the more accurate COVID-19 testing uses RT-PCR to evaluate whether there is SAR-CoV-2 RNA in the collected samples. It is almost certain that the subject is infected with the virus...
We value your privacy We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies. Our Privacy Policy